- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Oric Pharmaceuticals Inc (ORIC)
Oric Pharmaceuticals Inc stock price live, this page displays NASDAQ ORIC stock exchange data. View the ORIC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Oric Pharmaceuticals Inc real time stock price chart below.
What Is the Oric Pharmaceuticals Inc Stock Price Today?
The Oric Pharmaceuticals Inc stock price today is 14.43.
What Is the Stock Symbol for Oric Pharmaceuticals Inc?
The stock symbol for Oric Pharmaceuticals Inc is "ORIC."
What Stock Exchange Does Oric Pharmaceuticals Inc Trade On?
Oric Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Oric Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Oric Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ORIC quote. (ISIN: US68622P1093)
What Is the Oric Pharmaceuticals Inc Stock Price Today?
The Oric Pharmaceuticals Inc stock price today is 14.43.
What Is the Stock Symbol for Oric Pharmaceuticals Inc?
The stock symbol for Oric Pharmaceuticals Inc is "ORIC."
What Stock Exchange Does Oric Pharmaceuticals Inc Trade On?
Oric Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Oric Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Oric Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ORIC quote. (ISIN: US68622P1093)
14.43
+0.51(+3.66%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.09
14.65
52 wk Range
7.23
14.93
ORIC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.0914.65
52 wk Range
7.2314.93
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ORIC Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
20.67
Upside
+43.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
9 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.67
(+43.22% Upside)
Earnings
Latest Release
Aug 03, 2026
EPS / Forecast
-0.38 / -0.36
Revenue / Forecast
-- / --
Compare ORIC to Peers and Sector
Metrics to compare | ORIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORICPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.6x | −2.7x | −0.3x | |
PEG Ratio | −0.36 | −0.04 | 0.00 | |
Price/Book | 3.9x | 3.6x | 2.6x | |
Price / LTM Sales | - | 71.5x | 3.1x | |
Upside (Analyst Target) | 54.5% | 152.1% | 50.4% | |
Fair Value Upside | Unlock | 0.3% | 6.4% | Unlock |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Oric Pharma (ORIC) Stock Price Today?
The Oric Pharma stock price today is 14.43 USD.
What Stock Exchange Does Oric Pharma Trade On?
Oric Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Oric Pharma?
The stock symbol for Oric Pharma is "ORIC."
What Is the Oric Pharma Market Cap?
As of today, Oric Pharma market cap is 1.50B USD.
What Is Oric Pharma's Earnings Per Share (TTM)?
The Oric Pharma EPS (TTM) is -1.35.
When Is the Next Oric Pharma Earnings Date?
Oric Pharma will release its next earnings report on Nov 09, 2026.
From a Technical Analysis Perspective, Is ORIC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Oric Pharma Stock Split?
Oric Pharma has split 0 times.
How Many Employees Does Oric Pharma Have?
Oric Pharma has 111 employees.
What is the current trading status of Oric Pharma (ORIC)?
As of Aug 19, 2026, Oric Pharma (ORIC) is trading at a price of 14.43 USD, with a previous close of 13.92 USD. The stock has fluctuated within a day range of 14.09 USD to 14.65 USD, while its 52-week range spans from 7.23 USD to 14.93 USD.
What Is Oric Pharma (ORIC) Price Target According to Analysts?
The average 12-month price target for Oric Pharma is 20.67 USD, with a high estimate of 27 USD and a low estimate of 14 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +43.22% Upside potential.
What Is the ORIC Premarket Price?
ORIC's last pre-market stock price is 14.16 USD. The pre-market share volume is 1,140.00, and the stock has decreased by 0.24, or 1.72%.
What Is the ORIC After Hours Price?
ORIC's last after hours stock price is 13.84 USD, the stock has decreased by -0.08, or -0.57%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.